Taken together with our recent finding that BM-derived CD362+ hMSCs can ameliorate E. coli-induced injury, these data provide important insights regarding the therapeutic potential of a defined subset of hMSCs, specifically CD362+ for pneumonia. Here, SDC2 is linked to pneumonia.